NSCLC is one of the most dynamic indications in oncology. In the United States, the FDAapproved six new therapies for NSCLC in 2015 and, in 2016, granted approval to Tecentriq (Roche/Genentech), the third immune checkpoint inhibitor to launch for this indication. In addition, Keytruda (Merck & Co.) is the first PD-1 inhibitor to enter the commercially lucrative first-line metastatic NSCLC setting, with an FDA label expansion awarded for PD-L1-positive patients in 2016. As a result, the current treatment algorithm for metastatic NSCLC is continuously evolving, including in biomarker-driven populations such as EGFR-mutation-positive and ALK-translocation-negative patients.
- What is the uptake of Keytruda in the first-line metastatic NSCLC setting, according to surveyed U.S. medical oncologists?
- What percentage of second-line metastatic patients receive the recently approved agent Tecentriq, and which factors drive prescribing?
- What is the most preferred sequence of treatment in select biomarker-defined metastatic NSCLC populations?
- How do drug-treatment rates vary between key metastatic NSCLC patient segments, according to biomarker status and line of therapy?
Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.